 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || AVT001 / Avotres
Trial completion: Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes (clinicaltrials.gov) - Jul 9, 2024
P1/2, N=25, Completed, Sponsor: Avotres Inc.
Active, not recruiting --> Completed
- || AVT001 / Avotres
Clinical, Journal: Novel Autologous Dendritic Cell Therapy AVT001 for Type 1 Diabetes. (Pubmed Central) - Jun 25, 2024
P1/2
(Funded by Avotres Inc. and the Division of Diabetes, Endocrinology, and Metabolic Diseases; ClinicalTrials.gov number, NCT03895996.).
- AVT001 / Avotres
Novel Autologous Dendritic Cell Therapy AVT001 for Type 1 Diabetes (Poster Halls B-C; [Board No. 825]) - Apr 10, 2023 - Abstract #ADA2023ADA_1437;
At day 150, the C-peptide AUCs were significantly different between groups, namely 0.518 (0.430) and 0.472 (0.134) respectively. Per MMRM, the least square mean difference between AVT001 and placebo at day 150, is estimated to be 0.172 (p=
- AVT001 / Avotres
Novel Autologous Dendritic Cell Therapy AVT001 for Type 1 Diabetes (Exhibit Hall (ePoster Theater B); [Board No. 825]) - Apr 10, 2023 - Abstract #ADA2023ADA_947;
At day 150, the C-peptide AUCs were significantly different between groups, namely 0.518 (0.430) and 0.472 (0.134) respectively. Per MMRM, the least square mean difference between AVT001 and placebo at day 150, is estimated to be 0.172 (p=
- | AVT001 / Avotres
Trial completion date: Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes (clinicaltrials.gov) - Dec 12, 2022
P1/2, N=24, Active, not recruiting, Sponsor: Avotres Inc.
Per MMRM, the least square mean difference between AVT001 and placebo at day 150, is estimated to be 0.172 (p= Trial completion date: Sep 2023 --> Dec 2023
- | AVT001 / Avotres
Enrollment closed: Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes (clinicaltrials.gov) - Dec 7, 2021
P1/2, N=24, Active, not recruiting, Sponsor: Avotres Inc.
Trial completion date: Sep 2023 --> Dec 2023 Recruiting --> Active, not recruiting
- | AVT001 / Avotres
Trial completion date, Trial primary completion date: Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes (clinicaltrials.gov) - Apr 22, 2021
P1/2, N=24, Recruiting, Sponsor: Avotres Inc.
Recruiting --> Active, not recruiting Trial completion date: Jun 2022 --> Sep 2023 | Trial primary completion date: Nov 2020 --> Feb 2022
- | AVT001 / Avotres
Enrollment open: Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes (clinicaltrials.gov) - May 9, 2019
P1/2, N=24, Recruiting, Sponsor: Avotres Inc.
Trial completion date: Jun 2022 --> Sep 2023 | Trial primary completion date: Nov 2020 --> Feb 2022 Not yet recruiting --> Recruiting
- | AVT001 / Avotres
New P1/2 trial: Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes (clinicaltrials.gov) - Mar 29, 2019
P1/2, N=24, Not yet recruiting, Sponsor: Avotres Inc.